宣泰医药
(688247)
| 流通市值：45.74亿 | | | 总市值：45.74亿 |
| 流通股本：4.53亿 | | | 总股本：4.53亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 191,160,204.92 | 94,546,671.06 | 446,568,888.08 | 331,464,771.67 |
| 营业收入 | 191,160,204.92 | 94,546,671.06 | 446,568,888.08 | 331,464,771.67 |
| 二、营业总成本 | 173,790,467.08 | 82,432,049.12 | 394,329,144.83 | 276,521,555.79 |
| 营业成本 | 111,768,168.21 | 57,696,405.85 | 270,542,117.19 | 196,182,373.59 |
| 税金及附加 | 1,679,123.11 | 936,899.05 | 3,383,378.44 | 2,589,019.59 |
| 销售费用 | 5,895,390.84 | 2,247,487.02 | 9,868,874.61 | 7,746,597.15 |
| 管理费用 | 19,443,847.85 | 8,343,884.6 | 37,131,600.71 | 28,823,979.19 |
| 研发费用 | 31,998,413.62 | 11,973,009.88 | 74,939,615.69 | 42,889,476.72 |
| 财务费用 | 3,005,523.45 | 1,234,362.72 | -1,536,441.81 | -1,709,890.45 |
| 其中:利息费用 | 533.77 | 81.74 | 1,411.72 | 1,132.17 |
| 其中:利息收入 | 1,906,322.17 | 1,475,052.1 | 5,320,657.35 | 3,381,610.27 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | 1,341,275.35 | - |
| 加:投资收益 | 7,715,066 | 617,185.25 | 9,911,414.57 | 9,181,763.05 |
| 资产减值损失(新) | -891,116.42 | -238,144.97 | -17,539,733.26 | -865,370.19 |
| 信用减值损失(新) | 2,988,454.54 | 1,468,545.63 | -1,453,006.6 | 1,521,203.91 |
| 其他收益 | 2,767,356.1 | 962,574.71 | 10,819,130.92 | 4,787,542.56 |
| 四、营业利润 | 29,949,498.06 | 14,924,782.56 | 55,318,824.23 | 69,568,355.21 |
| 加:营业外收入 | 3,470,415.29 | 3,468,974.8 | 37,308.85 | 8,763.49 |
| 减:营业外支出 | 1,288,254.74 | 18,460.71 | 2,020,799.66 | 279,441.15 |
| 五、利润总额 | 32,131,658.61 | 18,375,296.65 | 53,335,333.42 | 69,297,677.55 |
| 减:所得税费用 | 2,429,880.66 | 1,811,958.4 | 5,852,518.73 | 5,835,210.76 |
| 六、净利润 | 29,701,777.95 | 16,563,338.25 | 47,482,814.69 | 63,462,466.79 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 29,701,777.95 | 16,563,338.25 | 47,482,814.69 | 63,462,466.79 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 29,701,777.95 | 16,563,338.25 | 47,482,814.69 | 63,462,466.79 |
| 扣除非经常损益后的净利润 | 20,377,532.18 | 12,491,038.42 | 31,333,993.96 | 53,880,715.31 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.07 | 0.04 | 0.11 | 0.14 |
| (二)稀释每股收益 | 0.07 | 0.04 | 0.11 | 0.14 |
| 八、其他综合收益 | -32,756.85 | -16,043.8 | -20,861.17 | -12,932.76 |
| 归属于母公司股东的其他综合收益 | -32,756.85 | -16,043.8 | -20,861.17 | -12,932.76 |
| 九、综合收益总额 | 29,669,021.1 | 16,547,294.45 | 47,461,953.52 | 63,449,534.03 |
| 归属于母公司股东的综合收益总额 | 29,669,021.1 | 16,547,294.45 | 47,461,953.52 | 63,449,534.03 |
| 公告日期 | 2026-08-28 | 2026-04-30 | 2026-04-30 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |